

FACSIMILE COVER SHEET**Licata & Tyrrell P.C.**66 E. Main Street
Marlton, New Jersey

Tel: (856) 810-1515

Fax: (856) 810-1454

November 10, 2003

RECEIVED
CENTRAL FAX CENTER

NOV 10 2003


OFFICIAL

GROUP: 1635**FAX NUMBER: 1-703-872-9306****ATTORNEY DOCKET NO.: ISPH-0613****SERIAL NO.: 10/054,313****FILED: October 22, 2001****NUMBER OF PAGES: 10**
(including this sheet)**MESSAGE:** Attached is an Amendment Transmittal Letter (in duplicate) and
Reply to Restriction Requirement dated October 9, 2003.**URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!**

* * * * *

If you have any questions, or did not receive the proper number of pages, or had trouble
during transmission, please call 856-810-1515.**CONFIDENTIALITY NOTICE**

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

AMENDMENT TRANSMITTAL LETTER (Large Entity)			Dock t No. ISPH-0613		
Applicant(s): Crooke et al.					
Serial No. 10/054,313	Filing Date October 22, 2001	Examiner James Schultz	Group Art Unit 1635		
Invention: HUMAN RNASE H AND COMPOSITIONS AND USES THEREOF					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	45 -	45 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	19 -	19 =	0 x	\$86.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<div style="margin-top: 20px;"><input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div>					
<div style="text-align: center;"> _____ Signature</div> <div>Jane Massey Licata Reg. No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454</div>			Dated: November 10, 2003		
<div>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</div> <div style="text-align: center; margin-top: 10px;">_____ Signature of Person Mailing Correspondence</div> <div style="text-align: center; margin-top: 10px;">_____ Typed or Printed Name of Person Mailing Correspondence</div>					
cc:					

RECEIVED
CENTRAL POST OFFICE

NOV 10 2003

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0613
Inventors: Crooke et al.
Serial No.: 10/054,313
Filing Date: October 22, 2001
Examiner: James Schultz
Group Art Unit: 1635
Title: Human RNase H and Compositions and Uses
Thereof

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile
transmitted to the Patent and Trademark Office on
the date shown below.

On November 10, 2003

James Massey
James Massey Licata Registration No. 32,257

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

REPLY TO RESTRICTION REQUIREMENT

This reply is to the Restriction Requirement mailed October 9,
2003, setting a one (1) month statutory period for response.
Please enter the following remarks into the record. No new matter
has been added by this response.

Remarks begin on page 2 of this paper.

Attorney Docket No.: ISPH-0613
Inventors: Crooke et al.
Serial No.: 10/054,313
Filing Date: October 22, 2001
Page 2

REMARKS

Claims 1-45 are pending in the instant application. The pending claims have been subjected to a Restriction Requirement under 35 USC §121 and 37 C.F.R. 1.141, as containing multiple independent sequences, comprising multiple inventions.

The Examiner suggests that there are five distinct inventions in the present application and requires restriction under 35 U.S.C. 121. The Examiner further suggests that present invention comprises five distinct groups:

Group I) Claims 1-13 and 22 drawn to an RNase H polypeptide that may be an RNase HI or type 2 RNase H polypeptide and compositions comprising pharmaceutical carriers or antisense and said RNase H, classified for example in class 435, subclass 183.

Group II) Claims 14-19, 24-26, 44 and 45 drawn to an isolated polynucleotide encoding RNase H which may be RNase HI or type 2 RNase H, and compositions comprising pharmaceutical carriers or antisense with said RNase H polynucleotide and vectors and cells thereof, and methods of use, classified in class 536, subclass 23.1.

Group III) Claim 20, drawn to an antibody targeted to a human type 2 RNase H, classified in class 530, subclass 387.1.

Attorney Docket No.: ISPH-0613
Inventors: Crooke et al.
Serial No.: 10/054,313
Filing Date: October 22, 2001
Page 3

Group IV) Claims 21,23, and 27-36, drawn to nucleic acid probes and antisense directed to human RNase HI or human type 2 RNase H, and to methods of screening therefore, classified, for example, in class 536, subclass 24.5.

Group V) Claims 37-43, drawn to a method of identifying agents which increase or decrease activity of an RNase H polypeptide, classified for example in class 435, subclass 6.

The Examiner further suggests that groups I-V are unrelated to each other as they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP 806.4, MPEP 808.01). The Examiner suggests that the different groups each comprise chemical structures which are independent of one another and not disclosed as capable of use together, and have different modes of operation. The Examiner further suggests that the polypeptide of Group I is not disclosed as being used in any method with either the polynucleotide of Group II or the antibody of Group III and that the polynucleotide of Group II is not disclosed as being used with the antibody of Group III. It is further suggested that the polypeptide of Group I is an enzyme that cleaves RNA/DNA hybrids, and functions differently than the polynucleotide of Group II and the antibody of Group III, which are not disclosed

Attorney Docket No.: ISPH-0613
Inventors: Crooke et al.
Serial No.: 10/054,313
Filing Date: October 22, 2001
Page 4

as having catalytic activity. The Examiner suggests that the antibody of Group III binds specifically to molecules based on complex tertiary structure, and that this feature is not shared by the polynucleotide of Group II.

The Examiner further suggests that the antisense of Group IV is unrelated to the polynucleotide of Group II and the antibody of Group III because the antisense molecules of Group IV are not disclosed as being used in any method with the polynucleotide of Group II and the antibody of Group III.

Lastly, the Examiner suggests that the method of Group V for identifying agents that increase or decrease activity of an RNase H polypeptide is drawn to screening a broad class of agents that include small molecule inhibitors, and involve steps such as measuring the activity of RNase H that are not shared with any other group.

The Examiner suggests that these inventions are distinct for the above reasons, and have acquired a separate status in the art, as shown by their different classification.

Applicants respectfully traverse this restriction requirement.

MPEP 803 states that for proper restriction (1) the claimed inventions are independent or distinct (2) search and examination

Attorney Docket No.: ISPH-0613
Inventors: Crooke et al.
Serial No.: 10/054,313
Filing Date: October 22, 2001
Page 5

of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions.

MPEP 808.01 states that where the inventions claimed are independent, i.e., where they are not connected in design, operation, or effect under the disclosure of the particular application under consideration, the facts relied on for this conclusion are in essence the reasons for insisting upon restriction. MPEP 802.1 defines "distinct" as two or more subjects as disclosed are related.

In the present invention, the claims relate to polypeptides which have been identified as novel human Type 2 RNase by homology between amino acid sequences (please see Specification page 6, lines 5-7) and antisense inhibition of expression of a target protein via the use of human Type 2 RNase H (please see Specification page 6, lines 26-28). By definition, the groups cannot be independent because the polypeptides share homology and Type 2 characteristics. Therefore, there is a disclosed relationship between the polypeptides.

Applicants respectfully request reconsideration and withdrawal of the restriction requirement.

Attorney Docket No.: ISPH-0613
Inventors: Crooke et al.
Serial No.: 10/054,313
Filing Date: October 22, 2001
Page 6

However, in an earnest effort to be fully responsive and facilitate prosecution of this application, Applicants elect to prosecute Group II, an isolated polypeptide encoding RNase H and compositions comprising pharmaceutical carriers or antisense with said RNase H polypeptide, and vectors, cells, and methods of use.

Applicants do not believe that claims 24-26 properly belong in Group II, as they are directed to methods of enhancing inhibition of a selected protein using an antisense oligonucleotide and a human Type 2 RNase H polypeptide, not a polynucleotide.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: November 10, 2003

Licata & Tyrrell P.C.
66 Main Street
Marlton, NJ 08053

856-810-1515